Birchview Capital LP Invests $112,000 in NeuroPace, Inc. (NASDAQ:NPCE)

Birchview Capital LP acquired a new stake in NeuroPace, Inc. (NASDAQ:NPCE) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $112,000.

Several other institutional investors have also bought and sold shares of the company. Wells Fargo & Company MN increased its position in NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock worth $73,000 after buying an additional 2,279 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after acquiring an additional 6,181 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in NeuroPace in the 4th quarter worth about $103,000. Palumbo Wealth Management LLC bought a new stake in NeuroPace in the 4th quarter valued at about $129,000. Finally, Barclays PLC lifted its holdings in NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Activity at NeuroPace

In other news, insider Martha Morrell sold 78,334 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $13.72, for a total value of $1,074,742.48. Following the transaction, the insider now owns 81,993 shares of the company’s stock, valued at $1,124,943.96. This represents a 48.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ltd. Kck sold 5,270,845 shares of NeuroPace stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,349,279 shares of company stock valued at $50,622,185. Company insiders own 22.20% of the company’s stock.

NeuroPace Price Performance

Shares of NASDAQ:NPCE opened at $11.15 on Friday. The company has a 50 day moving average of $11.76 and a 200 day moving average of $10.86. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The stock has a market cap of $365.20 million, a P/E ratio of -11.15 and a beta of 2.03. NeuroPace, Inc. has a 12 month low of $5.45 and a 12 month high of $15.11.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07. The firm had revenue of $21.47 million during the quarter, compared to the consensus estimate of $21.14 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. As a group, sell-side analysts forecast that NeuroPace, Inc. will post -1 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price target on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, January 30th. Cantor Fitzgerald lifted their price objective on shares of NeuroPace from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Finally, UBS Group started coverage on NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, NeuroPace currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.20.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.